Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rovi and Recordati Deemed Top Picks By Analyst

Executive Summary

The team at Jefferies believe that the Spanish and Italian firms, as well as Hikma, are looking like good bets for the year ahead.


Related Content

Rovi rolls out Becat enoxaparin in Europe
Watch Out GSK: Vectura And Hikma Target Ellipta Portfolio
J&J Pharma Growth Led By Oncology; Firm Tries To Assuage Zytiga Concerns
Allergan's Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection
Esmya Review Held Back Gedeon Richter in First Half
Liver Damage Worries Lead To Further EU Restrictions On Richter’s Esmya
Hikma's CRL Proves GSK's Witty Was Right: Generic Advair Is Hard


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts